一名分析師周五說(shuō)Mylan因?yàn)樘岣咚巸r(jià)而可能面臨價(jià)格審查，結(jié)果Mylan股價(jià)下降6%格郁，看看今天中國(guó)股市，這點(diǎn)降不是痛惰聂。Myan也挺敢干煮剧，24個(gè)產(chǎn)品藥價(jià)至少提高20%，其中7個(gè)產(chǎn)品提高100%以上烂琴。中國(guó)藥企只有羨慕的份兒滚澜，這點(diǎn)看出美國(guó)政府真不行粗仓。Mylan發(fā)言人說(shuō)分析師的說(shuō)法有缺陷，我們銷(xiāo)售1400個(gè)產(chǎn)品设捐，只有24個(gè)產(chǎn)品漲價(jià)借浊，你就唧唧歪歪。拉黑你萝招。
美國(guó)政府的確開(kāi)始審查開(kāi)始漲價(jià)的四個(gè)藥企蚂斤。
原文如下
Analyst suggests Mylan could face price scrutiny
(Ref: Bloomberg, The Street, Investor's Business Daily, CNBC)
June 10th, 2016
By: Joe Barber
An analyst at Wells Fargo hinted on Friday that Mylan could become the next drugmaker to face scrutiny over its pricing practices, sending shares in the company down as much as 6 percent. Analyst David Maris noted that the company has implemented price hikes of at least 20 percent on 24 products, including hikes of more than 100 percent for seven products, within the last six months. "Given the regulatory environment, these pricing actions could bring greater scrutiny and headline risk," Maris stated.
Maris specifically cited a 542-percent price increase for the therapy ursodiol, a 444 percent increase for metoclopramide and a hike of 400 percent for dicyclomine. The analyst also noted a 56-percent price increase for tolterodine, while he said the drugmaker increased the price of Epi-Pen by 15 percent last month.
"We believe that given the regulatory environment, these pricing actions could bring greater regulatory scrutiny and headline risk," Maris suggested, adding "additionally, we wonder if aggressive price increases are being used to make EPS targets or to offset disappointing sales in other areas."
Commenting on the news, Mylan spokeswoman Nina Devlin argued that the company's business model "is not today, nor has it ever been, premised on price hikes," continuing "a flawed analysis focusing on a small number of products out of the more than 1400 products Mylan sells globally and the approximatively 600 products we sell in North America is simply self-serving and misleading to investors."
The news comes after members of the US Congress accused four drugmakers, including Valeant Pharmaceuticals and Turing Pharmaceuticals, on focusing on profit as opposed to helping patients when enacting price increases. The US Senate Special Committee on Aging previously asked the drugmakers to justify large price increases on off-patent therapies, while, former Valeant CEO Michael Pearson acknowledged that the drugmaker was too aggressive in implementing price hikes for older products.
